Innate Pharma SA

IPHA

$170M

Micro Cap

NASDAQBiological Products, (No Diagnostic Substances)🇺🇸North AmericaMARSEILLE174 employees

Drugs in Pipeline

Phase 3 Programs

Upcoming Catalysts

Next Catalyst

Sep 17, 2026

11d

Market Overview

Stock performance and key metrics

IPHA News

Catalyst Timeline

1 upcoming, 0 past

EarningsNext

IPHA Earnings Report

Sep 17, 2026Confirmed

FQ end 2026-06

Drug Pipeline

MIS416

Phase 2

Secondary Progressive Multiple Sclerosis

IPH2101

Phase 2

Multiple Myeloma

Drug Name	Phase	Indication	Designations	Patent
MIS416	Phase 2	Secondary Progressive Multiple Sclerosis	-	-
IPH2101	Phase 2	Multiple Myeloma	-	-

📑

Catalyst DossierPRO

The full research note — thesis, the if-approved scenario, financials & smart money. Compiled by CeliA.

→

Catalyst Verdict

Full breakdown — the signals behind the verdict

Market-Implied Move

Regulatory Approvals

Frequently asked questions

What is in Innate Pharma SA's drug pipeline?→

CatalystAlert tracks 2 drug candidates in Innate Pharma SA's (IPHA) pipeline across Phase 2. Its lead program is MIS416 (Phase 2). Each drug's phase, indication and upcoming catalysts are listed on this page.

When is Innate Pharma SA's next FDA catalyst?→

Innate Pharma SA's (IPHA) next tracked catalyst is a Earnings expected September 17, 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.

How do I track IPHA biotech catalysts?→

Add IPHA to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Innate Pharma SA's live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.

Get Catalyst Alerts

Receive weekly digests of upcoming catalysts

Data is aggregated from public sources (FDA, SEC, ClinicalTrials.gov). While we strive for accuracy, information may be incomplete, delayed, or contain errors. Terms apply